Lillesand, M.; Austdal, M.; Mroz, J.; Skaland, I.; Gudlaugsson, E.; Jong, F.C.d.; Zuiverloon, T.C.M.; Engan, K.; Janssen, E.A.M.
Spatial Immune Profiling and AI-Based Classifiers Identify Predictors of BCG Therapy Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer. Cancers 2026, 18, 938.
https://doi.org/10.3390/cancers18060938
AMA Style
Lillesand M, Austdal M, Mroz J, Skaland I, Gudlaugsson E, Jong FCd, Zuiverloon TCM, Engan K, Janssen EAM.
Spatial Immune Profiling and AI-Based Classifiers Identify Predictors of BCG Therapy Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer. Cancers. 2026; 18(6):938.
https://doi.org/10.3390/cancers18060938
Chicago/Turabian Style
Lillesand, Melinda, Marie Austdal, Jakub Mroz, Ivar Skaland, Einar Gudlaugsson, Florus C. de Jong, Tahlita C. M. Zuiverloon, Kjersti Engan, and Emiel A. M. Janssen.
2026. "Spatial Immune Profiling and AI-Based Classifiers Identify Predictors of BCG Therapy Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer" Cancers 18, no. 6: 938.
https://doi.org/10.3390/cancers18060938
APA Style
Lillesand, M., Austdal, M., Mroz, J., Skaland, I., Gudlaugsson, E., Jong, F. C. d., Zuiverloon, T. C. M., Engan, K., & Janssen, E. A. M.
(2026). Spatial Immune Profiling and AI-Based Classifiers Identify Predictors of BCG Therapy Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer. Cancers, 18(6), 938.
https://doi.org/10.3390/cancers18060938
